STUDIES ON IN VITRO ACTIVITY OF T-1220 AND CLINICAL EXPERIENCE IN THE TREATMENT OF RESPIRATORY INFECTIONS

• Published in: CHEMOTHERAPY Vol. 25; no. 5; pp. 967 - 972
• Main Authors: YONEMOTO, YUKINORI, SAITO, SONOKO, WATANABE, AKIRA, SASAKI, MASAKO, OIZUMI, KOTARO, KONNO, KIYOSHI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1977
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.25.967

Antimicrobial activity of T-1220, a new penicillin derivative, was studied. The drug showed lower levels of MICs than those of Sulbenicillin against clinical isolates of Klebsiella pneumoniae and Pseudomonas aeruginosa. Clinical evaluation of the drug was made by intravenous administration to a total 7 cases with secondary respiratory tract infections with gram negative bacilli. In 2 cases the drug was withdrawn because of the onset of chill and fever during the drip infusion in a case and of eruption in the other. Of 5 cases treated with daily doses of 4 to 8 grams of T-1220 a day for the periods of 10 to 15 days, a case of infected lung cancer with Pseudomonas showed an excellent therapeutic response. A fairly good clinical response was seen in a case of infected lung cancer, but no positive response was obtained in the remaining 3 cases. No significant deterioration was observed in laboratory findings after the administration of T-1220.